{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:16:31Z","timestamp":1780708591126,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003808","name":"Hospital Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ebiom.2022.104219","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T18:53:12Z","timestamp":1660330392000},"page":"104219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002-2019)"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-1762","authenticated-orcid":false,"given":"Aimin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Pik-Shan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Ching-Wan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea On-Yan","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Chung-Ngor","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-3387","authenticated-orcid":false,"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ebiom.2022.104219_bib0001","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104219_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104219_bib0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104219_bib0004","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.15420\/ecr.2019.21","article-title":"Recent warnings about antihypertensive drugs and cancer risk: where do they come from?","volume":"15","author":"Battistoni","year":"2020","journal-title":"Eur Cardiol"},{"issue":"10267","key":"10.1016\/j.ebiom.2022.104219_bib0005","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(20)32374-6","article-title":"The Lancet Commission on diabetes: using data to transform diabetes care and patient lives","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet North Am Ed"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104219_bib0006","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104219_bib0007","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ebiom.2022.104219_bib0008","doi-asserted-by":"crossref","first-page":"g7607","DOI":"10.1136\/bmj.g7607","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0009","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1038\/s41598-019-45014-4","article-title":"Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies","volume":"9","author":"Seretis","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0010","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1186\/s12885-021-09067-x","article-title":"Blood pressure and risk of cancer: a Mendelian randomization study","volume":"21","author":"Chan","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104219_bib0011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1568009054629663","article-title":"Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer","volume":"5","author":"Uemura","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ebiom.2022.104219_bib0012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","article-title":"The role of angiotensin II in cancer metastasis: potential of renin-angiotensin system blockade as a treatment for cancer metastasis","volume":"151","author":"Ishikane","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104219_bib0013","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1470-2045(21)00033-4","article-title":"Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis","volume":"22","author":"Copland","year":"2021","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ebiom.2022.104219_bib0014","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium channel blockers and the risk of cancer","volume":"279","author":"Rosenberg","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104219_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40256-013-0058-8","article-title":"Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a critical review of the evidence","volume":"14","author":"D\u00e9zsi","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104219_bib0016","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.2337\/dci19-0003","article-title":"From Hong Kong Diabetes Register to JADE program to RAMP-DM for data-driven actions","volume":"42","author":"Chan","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104219_bib0017","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/dc20-0260","article-title":"Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong 2002-2016","volume":"43","author":"Yang","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104219_bib0018","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00125-019-05074-7","article-title":"Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001\u20132016: a retrospective cohort study","volume":"63","author":"Wu","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104219_bib0019","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/ije\/dyab252","article-title":"Data resource profile: the Hong Kong Diabetes Surveillance Database (HKDSD)","volume":"51","author":"Wu","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104219_bib0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/endrev\/bnab007","article-title":"Conducting real-world evidence studies on the clinical outcomes of diabetes treatments","volume":"42","author":"Schneeweiss","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ebiom.2022.104219_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109233","article-title":"Time-varying risk associations of renin angiotensin system inhibitors with pneumonia and related deaths in a cohort of 252,616 patients with diabetes (2002-2019)","volume":"185","author":"Yang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ebiom.2022.104219_bib0022","series-title":"Top Ten Cancers","year":"2021"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104219_bib0023","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s00125-020-05217-1","article-title":"Real-world evidence: the devil is in the detail","volume":"63","author":"Gokhale","year":"2020","journal-title":"Diabetologia"},{"issue":"23","key":"10.1016\/j.ebiom.2022.104219_bib0024","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104219_bib0025","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1213\/ANE.0000000000002787","article-title":"Five steps to successfully implement and evaluate propensity score matching in clinical research studies","volume":"127","author":"Staffa","year":"2018","journal-title":"Anesth Analg"},{"issue":"14","key":"10.1016\/j.ebiom.2022.104219_bib0026","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2022.104219_bib0027","series-title":"Dynamic Regression Models for Survival Data: Springer Science & Business Media","author":"Martinussen","year":"2006"},{"key":"10.1016\/j.ebiom.2022.104219_bib0028","series-title":"Multiple Imputation of Covariates by Substantive ModelCompatible Fully Conditional Specification, R Package \u2018smcfcs\u2019","author":"Jonathan","year":"2022"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104219_bib0029","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1177\/0962280219881168","article-title":"Imputing missing time-dependent covariate values for the discrete time Cox model","volume":"29","author":"Murad","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"7382","key":"10.1016\/j.ebiom.2022.104219_bib0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104219_bib0031","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time-varying exposure related problems in pharmacoepidemiology: an overview","volume":"27","author":"Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104219_bib0032","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrendo.2015.37","article-title":"Drug-subphenotype interactions for cancer in type 2 diabetes mellitus","volume":"11","author":"Yang","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104219_bib0033","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","year":"2011","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104219_bib0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2040-1124.2010.00063.x","article-title":"What can we learn from the recent blood glucose lowering megatrials?","volume":"2","author":"Chan","year":"2011","journal-title":"J Diabetes Investig"},{"issue":"9123","key":"10.1016\/j.ebiom.2022.104219_bib0037","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0038","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.2016.375","article-title":"The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer","volume":"116","author":"Mandilaras","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104219_bib0039","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: the Rotterdam Study","volume":"112","author":"Van der Knaap","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0141076814562718","article-title":"The environment and disease: association or causation? 1965","volume":"108","author":"Hill","year":"2015","journal-title":"J R Soc Med"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104219_bib0041","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep4.1891","article-title":"Risk associations of glycemic burden and obesity with liver cancer \u2013 a 10-year analysis of 16,410 patients with type 2 diabetes","volume":"6","author":"Mao","year":"2022","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104219_bib0042","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/dmrr.2287","article-title":"Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry","volume":"28","author":"Yang","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13293-019-0247-5","article-title":"Sex differences in the metabolic effects of the renin-angiotensin system","volume":"10","author":"White","year":"2019","journal-title":"Biol Sex Differ"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104219_bib0044","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1161\/ATVBAHA.120.314508","article-title":"Sex-specific regulation of inflammation and metabolic syndrome in obesity","volume":"40","author":"Ter Horst","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1373\/clinchem.2018.288332","article-title":"Differences between men and women in mortality and the health dimensions of the morbidity process","volume":"65","author":"Crimmins","year":"2019","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104219_bib0046","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0008-6363(01)00479-5","article-title":"Renin angiotensin system and gender differences in the cardiovascular system","volume":"53","author":"Fischer","year":"2002","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0047","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11906-012-0319-y","article-title":"The \u201chis and hers\u201d of the renin-angiotensin system","volume":"15","author":"Hilliard","year":"2013","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104219_bib0048","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00432-020-03445-x","article-title":"Risk of lung cancer and renin-angiotensin blockade: a concise review","volume":"147","author":"Rachow","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104219_bib0049","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0b013e3283621ea3","article-title":"Angiotensin receptor blockers: are they related to lung cancer?","volume":"31","author":"Rao","year":"2013","journal-title":"J Hypertens"},{"issue":"410","key":"10.1016\/j.ebiom.2022.104219_bib0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104219_bib0051","first-page":"141","article-title":"High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese","volume":"40","author":"Woo","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104219_bib0052","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104219_bib0053","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104219_bib0054","first-page":"1375","article-title":"The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome","volume":"21","author":"Li","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104219_bib0055","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.bjc.6600945","article-title":"Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study","volume":"88","author":"S\u00f8rensen","year":"2003","journal-title":"Br J Cancer"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:19:46Z","timestamp":1762456786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422004017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":55,"alternative-id":["S2352396422004017"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104219","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002-2019)","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104219"}}